Allergic Rhinitis - Pipeline Review, H1 2018

  • ID: 4482735
  • Drug Pipelines
  • 128 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • AlleCures Inc
  • Fountain Biopharma Inc
  • HAL Allergy BV
  • Laboratorios LETI SL
  • Stallergenes Greer plc
  • MORE
Allergic Rhinitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H1 2018, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 7, 11, 2, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • AlleCures Inc
  • Fountain Biopharma Inc
  • HAL Allergy BV
  • Laboratorios LETI SL
  • Stallergenes Greer plc
  • MORE
Introduction

Report Coverage

Allergic Rhinitis - Overview

Allergic Rhinitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Allergic Rhinitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Allergic Rhinitis - Companies Involved in Therapeutics Development

Accolade Pharmaceuticals LLC

AFFiRiS AG

ALK-Abello AS

AlleCures Inc

ASIT Biotech SA

Chong Kun Dang Pharmaceutical Corp

Chrysalis BioTherapeutics Inc

Fountain Biopharma Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

HAL Allergy BV

Intrommune Therapeutics

Laboratorios LETI SL

Paradigm Biopharmaceuticals Ltd

Sanofi

Stallergenes Greer plc

Taiho Pharmaceutical Co Ltd

Xencor Inc

Allergic Rhinitis - Drug Profiles

(azelastine hydrochloride + budesonide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(mometasone furoate + olopatadine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

854-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergens for Perennial Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arabinogalactan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bepotastine besilate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-174 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPC-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FB-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hdm-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KR-62980 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lactococcus lactis G121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levocabastine hydrochloride + mometasone furoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVP-1703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rag-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Seasonal Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize HRH1 for Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STG-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYM-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Asthma and Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-7195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zafi-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergic Rhinitis - Dormant Projects

Allergic Rhinitis - Discontinued Products

Allergic Rhinitis - Product Development Milestones

Featured News & Press Releases

Mar 05, 2018: Glenmark Pharmaceuticals Presents New Data on Ryaltris, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress

Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France

Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites

Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets

Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US

Dec 13, 2017: Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis

Nov 30, 2017: Newly published Phase IIb clinical results with gp-ASIT+ in the ALLERGY journal highlight outstanding clinical and remarkable immunological effects

Oct 23, 2017: Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting

Oct 12, 2017: ASIT biotech announces the Publication of Its First Clinical Data with gp-ASIT+ in the Journal of Allergy and Clinical Immunology

Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline with Acceptance Of Regulatory Submission And New Market Approval

Jul 03, 2017: ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI

Jun 19, 2017: ASIT biotech Discloses Comments from the Paul Ehrlich Institute and Presents Detailed Results on the Phase III Clinical Study of gp-ASIT+ at EAACI

May 16, 2017: Paradigm’s preclinical hay fever trial: peer-reviewed and published in leading scientific journal

Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis

Apr 04, 2017: ASIT Biotech Announces that it Has Achieved the Primary Endpoint of the Phase I/IIa Clinical Trial with its hdm-ASIT+ Product Candidate for House Dust Mite Rhinitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Allergic Rhinitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2018

Allergic Rhinitis - Pipeline by AFFiRiS AG, H1 2018

Allergic Rhinitis - Pipeline by ALK-Abello AS, H1 2018

Allergic Rhinitis - Pipeline by AlleCures Inc, H1 2018

Allergic Rhinitis - Pipeline by ASIT Biotech SA, H1 2018

Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018

Allergic Rhinitis - Pipeline by Fountain Biopharma Inc, H1 2018

Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2018

Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2018

Allergic Rhinitis - Pipeline by Intrommune Therapeutics, H1 2018

Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H1 2018

Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Allergic Rhinitis - Pipeline by Sanofi, H1 2018

Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H1 2018

Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Allergic Rhinitis - Pipeline by Xencor Inc, H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..2), H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..3), H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..4), H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..5), H1 2018

Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..6), H1 2018

Allergic Rhinitis - Discontinued Products, H1 2018

Allergic Rhinitis - Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development for Allergic Rhinitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Accolade Pharmaceuticals LLC
  • AFFiRiS AG
  • ALK-Abello AS
  • AlleCures Inc
  • ASIT Biotech SA
  • Chong Kun Dang Pharmaceutical Corp
  • Chrysalis BioTherapeutics Inc
  • Fountain Biopharma Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • HAL Allergy BV
  • Intrommune Therapeutics
  • Laboratorios LETI SL
  • Paradigm Biopharmaceuticals Ltd
  • Sanofi
  • Stallergenes Greer plc
  • Taiho Pharmaceutical Co Ltd
  • Xencor Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll